Return to Publications
April 2017
The latest news on research, treatment, prevention and education from the state's only National Cancer Institute-designated Comprehensive Cancer Center
Stein

'First in Human' Trial Defines Safe Dosage for Small Molecule Drug ONC201 for Solid Cancer Tumors

A 'first in human' clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That's according to Rutgers Cancer Institute of New Jersey researchers, including lead investigator and medical oncologist Mark N. Stein, MD, an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, whose work also showed early signs of clinical benefit in patients with advanced prostate and endometrial cancer.

Payne visit

Congressman Donald M. Payne, Jr., Visits Rutgers Cancer Institute of New Jersey at University Hospital

Representatives of the American Association for Cancer Research, Rutgers Cancer Institute of New Jersey and University Hospital recently met with Congressman Donald M. Payne, Jr. for a roundtable discussion highlighting progress and promise in cancer research, including advances made in colorectal cancer. Topics included the importance of robust and sustained funding for biomedical research and other issues such as access to care and cancer disparities. Following the discussion, Congressman Payne toured the laboratories, treatment infusion area and patient library at Rutgers Cancer Institute of New Jersey at University Hospital in Newark.

Carpizo

Direct Tumor Vaccination Shown to Induce Anti-Tumor Immunity in a Pancreatic Cancer Model

Building on their previous research focusing on vaccination within a tumor (intratumoral) for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early stage resected pancreatic cancer intratumoral vaccination induces an anti-tumor response. Led by Rutgers Cancer Institute surgical oncologist and Director of the Hepatobiliary Program Darren R. Carpizo, MD, PhD, associate professor of surgery and pharmacology at Rutgers Robert Wood Johnson Medical School, the work also showed a significant improvement in overall survival.

Welsh

Tackling Some of the Basic Building Blocks of Cancer

Research by Rutgers University investigators has resulted in the development of small molecule inhibitors that block a protein involved in the development of some cancers. At focus are TAM receptors, which when overexpressed can make too many proteins leading to cancer development, drug resistance and overall poor patient survival. Rutgers Cancer Institute of New Jersey associate research member William J. Welsh, PhD, who is the Norman H. Edelman Professor in Bioinformatics of Pharmacology at Rutgers Robert Wood Johnson Medical School, is the co-corresponding author of the work published recently in Scientific Reports.